Daiichi Sankyo

Invivoscribe submitted the LeukoStrat CDx FLT3 Mutation Assay as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.

The company submitted the test to Japanese regulators for approval as a companion diagnostic for Daiichi Sankyo's acute myeloid leukemia drug quizartinib.

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

HTG will use its EdgeSeq platform to develop a multi-target mRNA assay for Daiichi Sankyo and to profile tumor samples for Centre Léon Bérard.

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

The large PGx analysis might provide welcome data for those already supportive of genotyping in the context of warfarin, but will it convince detractors?

NEW YORK (GenomeWeb) – Agendia today announced a new deal with Daiichi Sankyo to use Agendia's oncology biomarker technology to evaluate new drugs from the Japanese drug firm currently in clinical trials.

By Adam Bonislawski
Biotech firm KineMed said this week that it has signed a research collaboration agreement with Pfizer to investigate therapies for metabolic diseases, particularly type 2 diabetes.

Roche said this week that European regulators have cleared its Cobas BRAF mutation companion diagnostic for the melanoma drug Zelboraf (vemurafenib).

Pages

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.